Beta Bionics Statistics
Total Valuation
Beta Bionics has a market cap or net worth of $560.55 million. The enterprise value is $348.72 million.
Important Dates
The last earnings date was Tuesday, February 17, 2026, after market close.
| Earnings Date | Feb 17, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Beta Bionics has 44.38 million shares outstanding. The number of shares has increased by 536.74% in one year.
| Current Share Class | 44.38M |
| Shares Outstanding | 44.38M |
| Shares Change (YoY) | +536.74% |
| Shares Change (QoQ) | +1.28% |
| Owned by Insiders (%) | 3.62% |
| Owned by Institutions (%) | 76.00% |
| Float | 24.29M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.59 |
| Forward PS | 4.15 |
| PB Ratio | 1.95 |
| P/TBV Ratio | 1.95 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.48 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.66, with a Debt / Equity ratio of 0.03.
| Current Ratio | 8.66 |
| Quick Ratio | 7.73 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -40.26% and return on invested capital (ROIC) is -23.69%.
| Return on Equity (ROE) | -40.26% |
| Return on Assets (ROA) | -18.73% |
| Return on Invested Capital (ROIC) | -23.69% |
| Return on Capital Employed (ROCE) | -24.07% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $237,562 |
| Profits Per Employee | -$173,460 |
| Employee Count | 422 |
| Asset Turnover | 0.42 |
| Inventory Turnover | 2.55 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -36.82% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -36.82% |
| 50-Day Moving Average | 19.99 |
| 200-Day Moving Average | 20.22 |
| Relative Strength Index (RSI) | 29.91 |
| Average Volume (20 Days) | 1,238,282 |
Short Selling Information
The latest short interest is 5.75 million, so 12.96% of the outstanding shares have been sold short.
| Short Interest | 5.75M |
| Short Previous Month | 5.48M |
| Short % of Shares Out | 12.96% |
| Short % of Float | 23.69% |
| Short Ratio (days to cover) | 3.76 |
Income Statement
In the last 12 months, Beta Bionics had revenue of $100.25 million and -$73.20 million in losses. Loss per share was -$1.81.
| Revenue | 100.25M |
| Gross Profit | 55.54M |
| Operating Income | -71.68M |
| Pretax Income | -73.20M |
| Net Income | -73.20M |
| EBITDA | -70.11M |
| EBIT | -71.68M |
| Loss Per Share | -$1.81 |
Full Income StatementBalance Sheet
The company has $219.13 million in cash and $7.30 million in debt, with a net cash position of $211.82 million or $4.77 per share.
| Cash & Cash Equivalents | 219.13M |
| Total Debt | 7.30M |
| Net Cash | 211.82M |
| Net Cash Per Share | $4.77 |
| Equity (Book Value) | 287.61M |
| Book Value Per Share | 6.48 |
| Working Capital | 236.98M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$50.93 million and capital expenditures -$5.30 million, giving a free cash flow of -$56.22 million.
| Operating Cash Flow | -50.93M |
| Capital Expenditures | -5.30M |
| Free Cash Flow | -56.22M |
| FCF Per Share | -$1.27 |
Full Cash Flow StatementMargins
Gross margin is 55.40%, with operating and profit margins of -71.50% and -73.02%.
| Gross Margin | 55.40% |
| Operating Margin | -71.50% |
| Pretax Margin | -73.02% |
| Profit Margin | -73.02% |
| EBITDA Margin | -69.93% |
| EBIT Margin | -71.50% |
| FCF Margin | n/a |
Dividends & Yields
Beta Bionics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -536.74% |
| Shareholder Yield | -536.74% |
| Earnings Yield | -13.06% |
| FCF Yield | -10.03% |
Analyst Forecast
The average price target for Beta Bionics is $26.73, which is 111.64% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $26.73 |
| Price Target Difference | 111.64% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | 31.72% |
| EPS Growth Forecast (5Y) | -3.52% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Beta Bionics has an Altman Z-Score of 11.19 and a Piotroski F-Score of 3.
| Altman Z-Score | 11.19 |
| Piotroski F-Score | 3 |
